Figure 3.
Cumulative proportion of response to additional doses of hepatitis B virus (HBV) vaccine among human immunodeficiency virus type 1 (HIV-1)–infected participants. Plot showing the cumulative proportion with immune response to additional doses of standard HBV vaccine among HIV-1–infected participants. Immune response was determined 6 months after completion of the initial vaccination series and 4 weeks after the first and third revaccination doses.